To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

Key facts

Sponsor

UCSF Benioff Children's Hospital Oakland

Principal Investigator

Ervin Epstein, MD

UCSF Benioff Children's Hospital Oakland

Intervention

GDC-0449(drug)

Enrollment

41 enrolled

Eligibility

35-75 years · All sexes

Timeline

2009 – 2014

Study locations (2)

• Children's Hospital Oakland Research Institiute, Oakland, California, United States
• Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gorlin syndrome

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT06050122
  Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
  Sol-Gel Technologies, Ltd.

See all trials for Gorlin syndrome →